AZD2014 + Everolimus + Fulvestrant
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor Positive Breast Cancer
Conditions
Estrogen Receptor Positive Breast Cancer
Trial Timeline
Jan 16, 2014 → Dec 31, 2021
NCT ID
NCT02216786About AZD2014 + Everolimus + Fulvestrant
AZD2014 + Everolimus + Fulvestrant is a phase 2 stage product being developed by AstraZeneca for Estrogen Receptor Positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02216786. Target conditions include Estrogen Receptor Positive Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02216786 | Phase 2 | Completed |
Competing Products
20 competing products in Estrogen Receptor Positive Breast Cancer